Furthermore, loss of CdGAP delayed tumor initiation, decreased tumor volume and tumor size in subcutaneous xenografts, and reduced distant metastasic burden in an orthotopic model of prostate cancer. This evidence concerns the gene ARHGAP31 and prostate cancer.